About Bridge Life Sciences
Bridge Life Sciences was set up to close the gap between the science and the investment case. Each report explains what a listed life science company is doing in the lab and what this could mean commercially, in language a general investor can follow.

Chris Kallos, CFA
Chris Kallos and the Bridge Life Sciences team produce every report in clear language, so a reader can follow both the science and the investment case.
Focus: ASX-listed therapeutics, diagnostics, medical technology and digital health companies.
Our research principles
Precision
Every number in a report is explained and sourced.
Professionalism
We use clear language, a consistent structure and a stated valuation method.
Reliability
The same rigorous analytical standards are applied to every company, every time.
Independence
Our conclusions are independent, regardless of who pays for coverage.
We are a focused life sciences research practice by design. We are selective about the ASX-listed companies we cover, so each one receives our full attention, and we work to the same high standard in every report.
General information only. See Legal and Disclaimer.